ALC

Business Context and Reporting Period

Company: Alcon, Inc. (Swiss corporation, majority-owned subsidiary of Nestlé S.A.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three months ended March 31, 2006
Filing Date: April 25, 2006
Business Overview: Global leader in ophthalmic products, operating through two segments: Alcon United States and Alcon International. Product categories include pharmaceuticals, surgical equipment/devices, and consumer eye care.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 8.1% year-over-year. On a constant currency basis, sales grew 10.5%, driven by volume growth across all segments.
• Profitability: Net earnings rose 18.5% to $295.7 million. Gross margin expanded to 75.1% due to favorable product mix, lower manufacturing costs, and reduced royalty expenses.
• Accounting Change (SFAS 123(R)): The company adopted SFAS No. 123(R) on January 1, 2006, requiring fair value recognition of share-based compensation. This adoption reduced Q1 2006 operating income by $31.3 million and net earnings by $21.1 million. Without this charge, year-over-year comparisons are not directly comparable.
• Segment Performance:
  • United States: Sales up 10.6%; Operating income up 15.2% to $284.0 million.
  • International: Sales up 5.7% (10.3% constant currency); Operating income up 11.4% to $235.9 million.
• Product Highlights:
  • Pharmaceuticals: Vigamox sales up 24.6%; Patanol up 25.8%; Travatan up 13.0%.
  • Surgical: Intraocular lens sales up 18.7%, driven by AcrySof ReSTOR and AcrySof Natural.
  • Consumer Eye Care: Systane artificial tears sales up 60.6%.

Guidance, Outlook, Risks, and Contingencies

• Dividend Outlook: Management expects to declare a dividend based on 2005 operations of approximately CHF 1.68 per share (~$1.29), totaling an estimated $399 million, subject to shareholder approval on May 2, 2006.
• Tax Rate: The Q1 effective tax rate was 16.5% (vs. 24.0% in 2005), benefiting from R&D funding in the U.S. and reserve releases. Management expects a full-year effective tax rate of 19% to 20% assuming retroactive extension of the U.S. research credit.
• Legal Contingency (AMO Litigation):
  • Alcon is appealing a December 2005 jury verdict awarding Advanced Medical Optics (AMO) $213.9 million in damages plus interest and fees. A total provision of $240.0 million was recorded in Q4 2005.
  • The court granted a stay on the injunction pending appeal, allowing Alcon to continue selling the Infiniti vision system. Alcon has developed an alternative cassette design to mitigate infringement risks.
• Reimbursement Risk: The Medicare Agency created a new "New Technology Intraocular Lens" (NTIOL) class offering an additional $50 reimbursement. Competitors' lenses are included; Alcon is pursuing similar classification for its AcrySof IQ lens. Failure to secure this could create a competitive disadvantage.
• Market Risks: Significant exposure to foreign currency fluctuations (hedged via derivatives) and interest rate changes on floating-rate debt. A 10% decline in foreign exchange rates could decrease pre-tax earnings by approximately $6.1 million.

Investor Verification Checklist

• Share-Based Compensation Impact: Verify the full-year impact of SFAS 123(R) adoption on operating margins, as Q1 included a $31.3 million charge representing ~40% of expected annual expense.
• AMO Litigation Status: Monitor the appeal process regarding the $240 million provision and the commercial impact of the alternative Infiniti cassette design.
• Dividend Approval: Confirm shareholder approval of the ~$399 million dividend at the May 2, 2006 annual meeting.
• Medicare Reimbursement: Track the outcome of Alcon's application for NTIOL classification for the AcrySof IQ lens to assess competitive positioning in the U.S. market.
• Constant Currency Growth: Distinguish between reported sales growth (8.1%) and constant currency growth (10.5%) to assess underlying operational performance versus FX headwinds.